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Recruitment of the RNA polymerase II (Pol II) tran-
scription initiation apparatus to promoters by
specific DNA-binding transcription factors is well
recognized as a key regulatory step in gene expres-
sion. We report here that promoter-proximal pausing
is a general feature of transcription by Pol II in
mammalian cells and thus an additional step where
regulation of gene expression occurs. This suggests
that some transcription factors recruit the transcrip-
tion apparatus to promoters, whereas others effect
promoter-proximal pause release. Indeed, we find
that the transcription factor c-Myc, a key regulator
of cellular proliferation, plays a major role in Pol II
pause release rather than Pol II recruitment at its
target genes. We discuss the implications of these
results for the role of c-Myc amplification in human
cancer.INTRODUCTION
Regulation of transcription is fundamental to the control of
cellular gene expression programs. Recruitment of the RNA
polymerase II (Pol II) transcription initiation apparatus to pro-
moters by specific DNA-binding transcription factors is generally
recognized as a key regulatory step in selective transcription at
most eukaryotic genes (Hochheimer and Tjian, 2003; Ptashne
and Gann, 1997; Roeder, 2005). Additional regulatory steps
can occur subsequent to recruitment of the transcription appa-
ratus, and these are known to play important roles in controlling
the expression of a subset of genes (Core and Lis, 2008; Margar-
itis and Holstege, 2008; Peterlin and Price, 2006).
Promoter-proximal pausing of Pol II is a postinitiation regula-
tory event that has beenwell-studied at a small number of genes.
Promoter-proximal pausing, for the purpose of discussion here,
will be used to describe events including attenuation, stalling,
poising, abortive elongation, and promoter-proximal termina-
tion. The Drosophila Hsp70 gene is regulated through both432 Cell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc.recruitment of the initiation apparatus and promoter-proximal
pausing prior to the transition to elongation (Gilmour and Lis,
1986; O’Brien and Lis, 1991; Rougvie and Lis, 1988). Paused
Pol II molecules can also be detected in some human genes
(Bentley and Groudine, 1986; Espinosa et al., 2003; Sawado
et al., 2003). At genes regulated through promoter-proximal
pausing, the pause factors DRB-sensitivity inducing factor
(DSIF) and negative elongation factor (NELF) generate a Pol II
pause just downstream of the transcription start site (TSS)
(Wada et al., 1998a; Yamaguchi et al., 1999). Certain
sequence-specific transcription factors may recruit pause-
release factors such as the positive transcription elongation
factor b (P-TEFb) to these genes (Barboric et al., 2001; Core
and Lis, 2008; Eberhardy and Farnham, 2001, 2002; Kanazawa
et al., 2003; Peterlin and Price, 2006).
Recent reports suggest that postinitiation regulation is impor-
tant for transcriptional control at a subset of metazoan protein-
coding genes. In human embryonic stem cells, for example,
approximately 30% of genes experience transcription initiation
but show no evidence of further elongation (Guenther et al.,
2007). These results indicate that a regulatory step subsequent
to recruitment of the initiation apparatus is key for transcriptional
control at these genes. Although the genes that experience
transcription initiation but not elongation are a minority, the
recent discovery that Pol II can initiate transcription in both the
sense and antisense directions (Core et al., 2008; Seila et al.,
2008) suggests that a postinitiation regulatory step may be
required more generally at promoters, if only to prevent unregu-
lated antisense transcription.
We report here evidence that promoter-proximal pausing does
occur generally in embryonic stem (ES) cells, at genes that are
fully transcribed as well as at genes that experience initiation
but not elongation. At genes with detectable levels of Pol II,
ChIP-Seq data revealed that most of the enzyme typically
occupies DNA in the promoter-proximal region together with
the pause factors DSIF and NELF. Inhibition of the pause-release
factor P-TEFb caused Pol II to remain at these sites genome-
wide. Because c-Myc plays key roles in ES cell self-renewal
and proliferation (Cartwright et al., 2005) and can bind the
pause-release factor P-TEFb in tumor cells (Eberhardy and Farn-
ham, 2001, 2002; Gargano et al., 2007; Kanazawa et al., 2003),
we investigated whether c-Myc functions to regulate pause
release in ES cells. Our results indicate that c-Myc plays a key
role in pause release rather than Pol II recruitment at a substantial
fraction of actively transcribed genes in ES cells.
RESULTS
Pol II Tends to Occupy Promoter Regions
We used chromatin immunoprecipitation coupled to high-
throughput sequencing (ChIP-seq) to determine how Pol II
occupies the ES cell genome (Figure 1, Table S1 and Table S2
available online). An antibody that binds to the N terminus of
the largest subunit of Pol II (N-20) was used, allowing us to
monitor Pol II independent of the phosphorylation status of its
C-terminal domain (CTD). We found that the bulk of Pol II occu-
pied the promoter-proximal region of the vast majority of genes
(Figure 1A). This tendency to occupy promoter-proximal regions
was evident both for genes that are actively transcribed (with
H3K4me3- and H3K79me2-modified nucleosomes) and for
nonproductive genes that show evidence of initiation but not
elongation (with H3K4me3-, but not H3K79me2-modified nucle-
osomes). At actively transcribed genes, low levels of Pol II signal
were observed throughout the transcribed region up to the
polyadenylation site, with higher signals observed downstream
where transcription termination takes place. These data are
consistent with more lengthy occupancy of promoter and termi-
nator regions than the central body of actively transcribed genes.
The presence of high polymerase density at the promoter
region relative to the gene body has previously been cited as
evidence for promoter-proximal pausing or some form of postin-
itiation regulation in E. coli, Drosophila, and human cells (Fuda
et al., 2009; Price, 2008; Wade and Struhl, 2008). The pattern
of Pol II binding we observed suggests that promoter-proximal
pausing occurs frequently in mouse embryonic stem (mES) cells.
To further characterize Pol II occupancy in mES cells, we calcu-
lated the relative ratio of Pol II density in the promoter-proximal
region and the gene body (Figure 1B), which has been termed
the traveling ratio (TR) (Reppas et al., 2006) or the pausing index
(Zeitlinger et al., 2007). At genes where the rate of promoter-
proximal clearance is similar to the rate of initiation, the TR is
close to 1 (Reppas et al., 2006). However, at genes where
promoter-proximal clearance is lower than the initiation rate,
the TR is greater than 1. Using this metric, we found that 91%
of genes have a Pol II TR of more than 2, confirming that higher
Pol II density is detected in the promoter-proximal region than in
the gene body at the vastmajority of genes (Figure 1C, Figure S1,
Table S3). The presence of high polymerase density in the
promoter regions of most active ES cell genes, where maximal
signal occurs 35 bp downstream of the transcriptional start
site, suggests that these genes experience some form of postin-
itiation regulation.
The large subunit of Pol II contains a CTD that is modified
at various stages of transcription; Pol II is recruited into the pre-
initiation complex with a hypophosphorylated CTD, and the CTD
is phosphorylated on serine 5 (Ser5P) during initiation and then
on serine 2 (Ser2P) during elongation (Fuda et al., 2009). To
determine how these two phosphorylated forms of Pol II occupy
ES cell genes, ChIP-Seq experiments were conducted withantibodies against these two phosphorylated forms of the CTD
(Figure 1A). Ser5P Pol II was detected in the promoter region
and the transcribed region of active genes, with the peak located
in the promoter-proximal region. For genes that experience
initiation but not elongation (nonproductive), Ser5P Pol II was
detected only within the promoter region, as expected. Ser2P
Pol II was detected predominantly downstream of the promoter
region, with the peak in the region downstream of the polyadeny-
lation site where termination likely takes place. These results are
consistent with the idea that Pol II typically experiences a
promoter-proximal, rate-limiting step after being recruited to
promoters and after becoming Ser5 phosphorylated. Pol II may
also experience a slow release from DNA in regions of transcrip-
tion termination (Core et al., 2008; Glover-Cutter et al., 2008).
P-TEFb Inhibition Prevents Pause Release
at Most Active Genes
The pattern of Pol II occupancy of genes suggests that a postin-
itiation regulatory step, such as pause release, may be important
for transcriptional control of most genes. The Drosophila Hsp70
gene is regulated subsequent to initiation by P-TEFb-dependent
pause release (Lis et al., 2000). Active P-TEFb, a heterodimer
consisting of the cyclin-dependent kinase Cdk9 and a cyclin
component (CycT1, CycT2, or CycK), phosphorylates at least
three targets important for transcriptional control: the Spt5
subunit of DSIF, the NelfE subunit of NELF, and Ser2 of the Pol
II CTD (Kim and Sharp, 2001; Marshall et al., 1996; Marshall
and Price, 1995; Wada et al., 1998b; Yamada et al., 2006). To
assess the role of P-TEFb-dependent pause release in global
transcriptional control, we repeated the ChIP-Seq experiment
for total Pol II in mES cells treated with flavopiridol (FP), an inhib-
itor of Cdk9 kinase activity (Chao et al., 2000; Chao and Price,
2001). As expected, FP treatment caused reduced phosphoryla-
tion of Spt5 and Pol II Ser2 within 60 min, whereas Ser5
phosphorylation was not substantially affected (Figure 2A and
Figure S2A). If Pol II pause release is required at transcribed
genes, we would expect that in the presence of FP, Pol II mole-
cules would remain associated with promoter-proximal pause
sites but be depleted from DNA farther downstream. This
change in the pattern of Pol II occupancy was observed at
most actively transcribed genes (Figure 2B and Figure S2B).
We analyzed TR to further evaluate changes in Pol II occupancy
genome-wide. TR changes with FP treatment were generally
observed at actively transcribed genes, where promoter-prox-
imal Pol II signals were relatively unaffected but Pol II signals
farther downstream were depleted (Figure 2C). We found that
75% of genes had a change in Pol II TR of at least 1.5 upon
drug treatment. TRs were generally unchanged at genes that
normally experience initiation but not elongation (Figure 2D).
These results suggest that P-TEFb-dependent pause release is
required for Pol II transcription of most actively transcribed
genes in mES cells.
Promoter-Proximal Sites Are Co-occupied by Pol II,
DSIF, and NELF
P-TEFb antagonizes the negative elongation activity of the pause
factors DSIF and NELF (Cheng and Price, 2007; Kim and Sharp,
2001; Wada et al., 1998b). DSIF (Spt4 and Spt5) and NELFCell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc. 433
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Figure 1. Genome-wide Occupancy of Pol II
(A) Occupancy of RNA Pol II (all), RNA Pol II Ser5P, and RNA Pol II Ser2P in mES cells, determined by ChIP-seq analysis. Enrichment at a representative active
gene (Rpl3) and nonproductive gene (Surb7) is shown. Genome-wide binding averages (introns not depicted), in 50 bp bins, are shown for each Pol II form
to display the general binding patterns along the transcription unit from 2 kb upstream of the transcriptional start site to 2.5 kb downstream of the end of
each annotated gene.
(B) Schematic representation describing the calculation used to determine the traveling ratio (TR) at each Pol II-bound gene in mES cells. The promoter-proximal
bin is defined using a fixed window from 30 bp to +300 bp around the annotated start site. The transcribed region (gene body) bin is from +300 bp to the
annotated end. The TR is the ratio of Pol II density in the promoter-proximal bin to the Pol II density in the transcribed region bin.
(C) Distribution of the percent of Pol II-bound genes with a given TR. Approximately 91% of genes have a TR greater than 2, indicating that the majority of Pol
II-bound genes have more Pol II in the promoter-proximal region compared to the downstream transcribed region.
See also Figure S1.(NelfA, NelfB, NelfC/D, and NelfE) are both associated with
promoter-proximal Pol II at genes regulated through pausing
(Wada et al., 1998a; Yamaguchi et al., 1999). Following the434 Cell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc.transition to elongation, NELF dissociates and a form of DSIF
remains associated with the elongation complex (Andrulis
et al., 2000; Wu et al., 2003). If P-TEFb-dependent pause release
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Figure 2. P-TEFb Inhibition Prevents
Release of Promoter-Proximal Pol II
(A) mES cells were treated with 1 mM flavopiridol
for the indicated time. Extracts were analyzed by
western blot using antibodies against Pol II
Ser2P, Spt5, Cdk9, and Brg1 (used as a loading
control). ** indicates higher-molecular-weight
Spt5 species, as reported in Yamada et al.
(2006), that is flavopiridol sensitive. * indicates
lower-molecular-weight Spt5 species. See also
Figure S2A.
(B) RNA Pol II (all) ChIP-seq analysis in mES cells
treated with control (DMSO for 60 min, black) or
flavopiridol (1 mM for 60 min, red). This panel
shows the changes in Pol II occupancy at four
example actively transcribed genes following
flavopiridol treatment. See also Figure S2B.
(C) Pol II traveling ratio distribution in flavopiridol-
treated (red) and control-treated (black) mES cells
for active genes (Pol II-bound with H3K79me2-
modified nucleosomes). Higher TR values indicate
a higher degree of pausing.
(D) Pol II traveling ratio distribution for nonpro-
ductive genes in mES cells (Pol II-bound but
withoutH3K79me2-modifiednucleosomes),demo-
nstrating that the TR distribution remains relatively
the same for nonproductive geneswhether treated
with control (black) or flavopiridol (red).is generally required at genes transcribed by Pol II, DSIF and
NELF should occupy the promoter-proximal regions of these
genes together with Pol II.
We used ChIP-Seq to determine the genome-wide occupancy
of NelfA (NELF) and Spt5 (DSIF) in murine ES cells (Figure 3).
The results revealed that NelfA and Spt5 occupy precisely the
same promoter-proximal sites as Pol II throughout the genome
(Figure 3A). The co-occupancy of Pol II, NelfA, and Spt5 in
promoter-proximal regions was evident at both actively tran-
scribed genes and genes that experience transcription initiation
but not elongation (nonproductive) (Figure 3A). Spt5 and NelfA
occupancy positively correlates with Pol II occupancy (Fig-
ure S3). The largest NelfA and Spt5 peaks were detected in the
promoter-proximal region, but only Spt5 was also enriched
farther downstream in actively transcribed genes (Figure 3A).
The Spt5 enrichment at the 30 end of actively transcribed genes
was similar to that of Ser2P Pol II, suggesting that it remains
associatedwith Pol II until termination. The NelfA and Spt5 peaks
overlapped with the promoter-proximal site of the Pol II peak,
which is flanked by H3K4me3-modified nucleosomes (Figures
3B and 3C). These results demonstrate that the pause factors
DSIF and NELF co-occupy the promoter-proximal regions of
genes together with Pol II, consistent with the model that
P-TEFb-dependent pause release is generally required at genes
transcribed by Pol II.
Factors such as the PAF1 complex are involved in postinitia-
tion events that are independent of promoter-proximal pausing.
PAF1 is involved in elongation, mRNA processing events, and
elongation-associated chromatin modifications (Saunders
et al., 2006). To test if the Pol II promoter-proximal peak isspecific for factors involved in promoter-proximal pausing, we
conducted ChIP-Seq with the Ctr9 subunit of the PAF1 complex.
Although a limited signal could be detected in the promoter-
proximal region of some genes, Ctr9 occupancy did not gener-
ally overlap with the promoter-proximal Pol II peak (Figure 3A).
Ctr9 was typically found within coding regions of active genes,
just downstream of promoter-proximal Pol II, and extending to
the 30 end of transcribed genes. Ctr9 occupancy peaked at the
30 end of actively transcribed genes, which is similar to the
results obtained for Ser2P Pol II and Spt5, suggesting that it
remains associated with Pol II until termination. The Ctr9 ChIP-
seq data indicate that the PAF1 complex generally associates
with the transcribed portion of most active genes, which is
consistent with its proposed roles in elongation, mRNA process-
ing, and chromatin modification (Adelman et al., 2006; Krogan
et al., 2003; Pokholok et al., 2002; Zhu et al., 2005). These results
support the view that the Pol II promoter-proximal peaks repre-
sent regions of postinitiation regulation and not simply an artifact
of the ChIP-Seq method.
DSIF and NELF function prior to P-TEFb at genes regulated by
pause release (Fuda et al., 2009; Peterlin and Price, 2006). This
predicts that DSIF and NELF should be present at promoter-
proximal sites with Pol II even without P-TEFb activity. We
used ChIP-chip to determine if Spt5 and NelfA co-occupy
promoter-proximal sites with Pol II following FP treatment. We
find that Spt5 and NelfA continue to co-occupy promoter-prox-
imal sites with Pol II following FP treatment (Figure S3B). Spt5
was depleted downstream of these promoter-proximal sites
following FP treatment, supporting the model that Spt5 localiza-
tion in the gene body is dependent on Pol II (Ni et al., 2004, 2008).Cell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc. 435
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Figure 3. DSIF and NELF Co-occupy Most Genes with Pol II
(A) Binding of Pol II (all), NelfA (NELF subunit), Spt5 (DSIF subunit), and Ctr9 (PAF1 subunit) using ChIP-seq analysis at a representative active gene (Rpl3) and
nonproductive gene (Surb7) in mES cells. Genome-wide binding averages (introns not depicted), in 50 bp bins, are shown for each factor to display the general
binding patterns along the transcription unit of RefSeq genes, from 2 kb upstream of the transcriptional start site to 2.5 kb downstream of the end of each
annotated gene.
(B) Heatmap representation of ChIP-seq binding for Pol II (all; blue), NelfA (orange), Spt5 (green), and H3K4me3 (purple) at all mouse RefSeq genes, rank ordered
from most Pol II to lowest Pol II. Color means enrichment, white means no enrichment. See also Figure S3.
(C) Spatial distribution of the distance (base pairs) of Spt5 (green), NelfA (orange), and H3K4me3 (purple) peaks from the promoter-proximal Pol II peak at each
enriched Pol II gene, demonstrating general overlaps with Spt5, NelfA, and Pol II peaks.
(D) ChIP-seq-binding plots showing Pol II (all), Spt5 (DSIF), NelfA (NELF), elongation-associated chromatin modification (H3K79me2), and TSSa-RNA reads that
map to this genomic region at a bidirectional initiated gene (Hsd17b12) and unidirectional initiated gene (Rpl6). Red arrows represent TSSa-RNA species thatmap
in the antisense direction to the gene, and blue arrows represent TSSa-RNA species that map in the sense direction to the gene.
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Figure 4. DSIF Knockdown Alters Pol II Occupancy at Many Genes
(A) Spt5 (left) and NelfA (right) protein levels after the indicated shRNA-
mediated knockdown in mES cells as determined by western blot using
Spt5 or NelfA antibodies. b-Tubulin protein is a loading control.
(B) RNA Pol II (all) ChIP-seq binding density in shControl (black), shSpt5
(orange), and shNelfA (blue)mEScells analysis at four activegenes inmEScells.
(C) RNA Pol II TR calculations in shControl, shSpt5, and shNelfA mES cells,
showing that many genes become less paused following Spt5 knockdown
and a more subtle change following NelfA knockdown. Lower TR values
indicate a lower degree of pausing.
See also Figure S4.These results indicate that DSIF and NELF co-occupy promoter-
proximal sites with Pol II prior to P-TEFb function.
Bidirectional and Unidirectional Genes
It was recently reported that Pol II can initiate transcription in
both the sense and antisense directions at many genes (Core
et al., 2008; Seila et al., 2008). We separated genes into bidirec-
tional and unidirectional classes based on evidence for sense
and antisense transcription start site associated RNAs (TSSa-
RNAs) in ES cells (Seila et al., 2008). To determine how DSIF
and NELF occupy the promoter-proximal regions of these two
classes of genes, we re-examined the ChIP-seq data for Pol II,
Spt5, NelfA, and H3K79me2 (a marker for elongation) at higher
resolution (Figure 3D). Approximately 65% of active genes with
TSSa-RNA reads fell into the bidirectional class, and at the
promoters of these genes we found that the two sites occupied
by Pol II were both co-occupied by NelfA and Spt5. Approxi-
mately 35% of active genes with TSSa-RNA reads fell into the
unidirectional class, and at the promoters of these genes we
found that the one site occupied by Pol II was co-occupied by
NelfA and Spt5. These results demonstrate that DSIF and
NELF generally co-occupy promoter-proximal regions wherever
Pol II is found, whether initiation is occurring in one direction or
two, further supporting themodel that P-TEFb-dependent pause
release is a general feature of transcription initiation by Pol II.
Pause-Factor Knockdown Alters Pol II Gene Occupancy
The pause factors NELF and DSIF co-occupy promoters with Pol
II at most genes that experience transcription initiation. Previous
studies have shown that loss of NELF causes a decrease in Pol II
density at promoters, and thus a decrease in Pol II traveling ratio
(or pausing index), at a small number of Drosophila genes (Muse
et al., 2007). To determine how loss of vertebrate NELF or DSIF
might influence Pol II occupancy, we used shRNA-mediated
knockdown of NelfA and Spt5 followed by Pol II ChIP-seq
analysis in mES cells (Figure 4).
The most significant change in Pol II density was found
following Spt5 knockdown, where increases in Pol II density
were frequently observed downstream of the promoter at
actively transcribed genes (Figure 4B). At these active genes,
depletion of a pausing factor appeared to result in increased
transcription through the pause site, but because there was
little effect on promoter-proximal Pol II, high rates of initiation
maintained Pol II promoter levels. NelfA was found to continue
to occupy the promoter-proximal regions following Spt5 knock-
down (Figures S4A and S4B). The effects of Spt5 knockdown on
Pol II density were quantified using the TR metric (Figure 4C and
Figures S4E and S4F). There was a substantial shift in TR upon
Spt5 knockdown, demonstrating that genes generally experi-
ence an increase in Pol II density in the transcribed region at
active genes when the levels of DSIF are reduced. These results
confirm that Spt5 function contributes to the control of promoter-
proximal Pol II in mES cells.
NelfA knockdown had less impact on Pol II occupancy (Fig-
ures 4B and 4C), but a modest effect was observed at some
genes and the pattern of change was similar to that observed
for the Spt5 knockdown experiment at nonproductive genes,
as evidenced by the change in TR (Figures S4E, S4F, andS4G). This result is similar to that observed previously in
Drosophila embryos, where a fraction of genes showed a loss
of Pol II density at the promoter (Muse et al., 2007). Spt5Cell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc. 437
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Figure 5. c-Myc Target Genes Are Enriched in
Actively Transcribed Genes and c-Myc/Max
Associates with P-TEFb in mES Cells
(A) Coimmunoprecipitation experiments in mES cells
using antibodies against IgG (tomeasure background
binding) or endogenous c-Myc, Max, Cdk9, and
CycT1. Proteins were immunopreipicated from mES
cell lysates and analyzed by western blot analysis
by probing for Max, Cdk9, and CycT1. Ten percent
input was loaded for the Max and Cdk9 blots, 1%
input was loaded for the CycT1 blot.
(B) Heatmap representation illustrating the transcrip-
tional state of c-Myc, Oct4, and Nanog target genes
in mES cells, as determined by Pol II Ser5P,
H3K4me3 (initiation-associated chromatin modifica-
tion), H3K79me2 (elongation-associated chromatin
modification), and H3K27me3 (repressive chromatin
modification). Each target gene set was rank ordered
based on the amount of Pol II bound at each gene,
from the highest amount of Pol II to the lowest
amount, and the enrichment of the indicated
chromatin modification or Pol II is displayed from
2.5 kb to +3 kb surrounding each annotated tran-
scription start site. Blue indicates enrichment and
white indicates no enrichment.
(C) c-Myc target genes have lower TR values than
nontarget genes. Histograms were made for the
number of genes with given TR values for high-confi-
dence c-Myc target genes and nontarget genes.
Genes with lower TR values are less paused than
genes with higher TR values.
See also Figure S5.occupancy was largely unaffected in the promoter-proximal
regions following NelfA knockdown (Figures S4C and S4D). In
summary, we find that Spt5 knockdown, and to a more limited
extent NelfA knockdown, can produce increased Pol II occu-
pancy in transcribed regions relative to promoter-proximal
regions, consistent with the proposed roles of these factors in
controlling promoter-proximal pausing.
c-Myc Binds P-TEFb and Contributes to Pause Release
in ES Cells
Certain DNA-binding transcription factors may be responsible
for recruiting P-TEFb to release paused polymerase at active
genes if P-TEFb-dependent pause release is a general feature
of transcription by Pol II. Such a role has been proposed for
c-Myc based on evidence that this transcription factor can
bind P-TEFb and stimulate elongation at specific genes in tumor
cells (Eberhardy and Farnham, 2001, 2002; Gargano et al., 2007;
Kanazawa et al., 2003). Because c-Myc is a key ES cell transcrip-
tion factor required for self-renewal and proliferation (Cartwright
et al., 2005), which occupies a third of active genes (see below),
we investigated whether c-Myc plays a role in P-TEFb-depen-
dent pause release at the genes it occupies in ES cells.
If c-Myc contributes to P-TEFb-dependent pause release
in ES cells, it might be expected to bind P-TEFb in these cells.
To function as a transcription factor, c-Myc forms a heterodimer438 Cell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc.with Max (Eilers and Eisenman, 2008). We used coimmunopreci-
pitation analysis to determine if endogenous c-Myc/Max inter-
acts with P-TEFb in ES cells. We found that immunoprecipitation
of P-TEFb components Cdk9 and CycT1 coimmunoprecipitates
Max, and similarly, immunoprecipitation of c-Myc and Max
coimmunoprecipitates Cdk9 and CycT1 (Figure 5A). Therefore,
c-Myc/Max can bind P-TEFb in ES cells.
If a predominant function of c-Myc is to contribute to pause
release in ES cells, then we expect that it should be associated
almost exclusively with actively transcribed genes, unlike other
key ES cell regulators like Oct4 andNanog, which are associated
with both active and repressed genes. We examined published
ChIP-Seq data to determine the fraction of genes bound by
c-Myc, Oct4, and Nanog that were actively transcribed (Chen
et al., 2008; Marson et al., 2008), as indicated by the presence
of nucleosomes containing histones H3K4me3 and H3K79me2
(Figure 5B). Just over half of Oct4- and Nanog-occupied genes
show evidence of transcription elongation (H3K79me2-modified
nucleosomes). In contrast, almost all of the c-Myc-occupied
genes have H3K79me2-modified nucleosomes, indicating that
the majority of c-Myc targets in mES cells experience transcrip-
tion elongation. Furthermore, c-Myc target genes have lower TR
values compared to non-c-Myc targets (Figure 5C). We estimate
that 33% of actively transcribed genes in ES cells are bound
by c-Myc within 1 kb of the transcriptional start site (Figure S5).
The association of c-Myc with a substantial fraction of actively
transcribed genes, coupled with evidence that it can bind
P-TEFb, is consistent with the model that c-Myc contributes to
P-TEFb-dependent pause release at a large portion of active
genes in ES cells.
To more directly test whether c-Myc regulates pause release,
we used a low-molecular-weight inhibitor of c-Myc/Max, 10058-
F4, which inhibits c-Myc/Max heterodimerization both in vitro
and in vivo (Hammoudeh et al., 2009; Wang et al., 2007; Yin
et al., 2003). Max co-occupies c-Myc-binding sites as deter-
mined byChIP, confirming that c-Myc andMax function together
at target genes in ES cells (Figure S6A). Treatment of mES cells
with 10058-F4 (50 mM for 6 hr) caused a decrease in the expres-
sion of most c-Myc target genes tested but did not affect
the expression of two non-c-Myc target genes, indicating that
c-Myc/Max function is inhibited by 10058-F4 under these condi-
tions (Figure 6A). The magnitude of the decrease observed
(20%–40%) is consistent with the relatively short duration of
inhibitor treatment relative to typical mRNA half-lives of 7 hr
in mES cells (Sharova et al., 2009).
If a key function of c-Myc is to contribute topause release at the
active genes it occupies in ES cells, then loss of c-Myc would be
expected to cause a reduction in the levels of Ser2-phosphory-
lated Pol II (the form associated with elongation) but should
not affect the levels of Ser5-phosphorylated Pol II (the form
associated with initiation). We found that treatment of ES cells
with 10058-F4 did indeed cause a significant reduction in the
levels of Pol II Ser2P, whereas Ser5P remained unaffected (Fig-
ure 6B). The 1/3 of genes that are regulated by c-Myc are among
themost highly transcribed genes in the cell, which likely explains
why the reduction in total Ser2P Pol II levels is greater than 33%.
If c-Myc regulates pause release, then inhibition should have
an effect on Pol II levels in promoter and gene bodies similar
to that of FP, but only at c-Myc-occupied genes. We tested
this idea by determining how 10058-F4 affects Pol II occupancy
using ChIP-seq in mES cells. There was little effect on Pol II
density at promoters, but there was a clear reduction in tran-
scribed regions (Figure 6C). This effect on Pol II density was
also observed following c-Myc shRNA knockdown (Figures
S6B–S6D). The magnitude of the effect with 10058-F4 was
somewhat milder than with FP, probably because the inhibition
of c-Myc/Max heterodimerization is not complete (Hammoudeh
et al., 2009; Wang et al., 2007; Yin et al., 2003). Treatment with
10058-F4 did not alter the protein levels of P-TEFb components
Cdk9 or CycT1, indicating that this effect is not a result of
reduced levels of P-TEFb (Figure S6E). Importantly, genes that
lack evidence of c-Myc binding showed patterns of Pol II occu-
pancy that were unaffected by treatment with 10058-F4 (Fig-
ure 6C). We confirmed that genes that are not targets of c-Myc
do require P-TEFb function to release paused Pol II by showing
that FP treatment causes a block in pause release (Figure 6C),
which suggests that transcription factors other than c-Myc are
involved in recruiting P-TEFb to stimulate pause release at these
genes.
We carried out amore global analysis of the effect of 10058-F4
on Pol II occupancy of genes bound by c-Myc and compared
these patterns to genes that are not bound by this factor but
show evidence of elongation (Figure 6D and Figure S6G). Theresults show that high-confidence c-Myc target genes generally
retained promoter-proximal Pol II but had reduced Pol II density
in their transcribed regions, whereas Pol II occupancy does not
change at genes that are not c-Myc targets (Figure 6D). Further
analysis confirmed that there were statistically significant
changes in the gene bodies (p = 7.341e-06) but not the promoter
regions (p = 0.4536) of c-Myc targets. Additionally, following
10058-F4 treatment, a substantial increase in TR was observed
at c-Myc target genes, but no such shift was observed at non-c-
Myc targets (Figure 6E). A similar shift in TR at the c-Myc target
genes was also detected following c-Myc shRNA knockdown,
indicating that genes become more paused (Figure S6F). The
observation that reduced c-Myc activity had little effect on
the levels of promoter-proximal Pol II but caused a reduction in
the levels of Pol II across transcribed portions of c-Myc target
genes is consistent with the model that c-Myc/Max generally
plays a role in Pol II pause release at its target genes inmES cells.
Loss of Oct4 and c-Myc Have Different Effects
on Pol II Gene Occupancy
Loss of another key ES cell transcription factor, Oct4, leads to
reduced transcription of many Oct4-bound active genes in ES
cells (Hall et al., 2009; Matoba et al., 2006). To determine how
loss of Oct4 affects Pol II levels at the promoters and transcribed
regions of its target genes, we utilized a doxycycline-inducible
Oct4 shutdown mES cell line (Niwa et al., 2000) and monitored
Pol II levels by ChIP-Seq before and after Oct4 shutdown (Fig-
ure 7). Oct4 protein levels were substantially reduced within
12 hr and nearly eliminated at 24 hr after exposure to doxycycline
(Figure 7A). At Oct4-occupied genes that experience reduced
transcription, Pol II occupancy was generally reduced in both
the promoter-proximal region and the gene body at 12 and
24 hr (Figure 7B). These effects were not observed atmost genes
that are not occupied by Oct4 (Figure 7B). The loss of Pol II in
the promoter-proximal regions of Oct4 target genes, given the
commensurate loss of Pol II in the gene body, is likely due to
reduced recruitment of the transcription apparatus. For these
Oct4 target genes, where Pol II is lost from both promoter-prox-
imal and gene body regions, we would expect no change in TR,
and a global analysis of such genes revealed that this is indeed
the case (Figure 7C and Figure S6G). We conclude that the
pattern of reduced Pol II density at Oct4 target genes that occurs
upon loss of Oct4 differs from that at c-Myc target genes upon
loss of c-Myc and suggest that this is due to differences in the
stages at which the two transcription factors play their dominant
regulatory roles.
DISCUSSION
Transcription factors bind to specific DNA sequences and regu-
late gene expression by recruiting the transcription initiation
apparatus to promoters (Hochheimer and Tjian, 2003; Ptashne
and Gann, 1997; Roeder, 2005). Recent studies have shown
that an additional level of regulation must occur subsequent to
initiation at certain genes and have proposed that certain tran-
scription factors regulate this step (Core and Lis, 2008; Margar-
itis and Holstege, 2008; Peterlin and Price, 2006). The evidence
described here indicates that promoter-proximal pausing isCell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc. 439
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Figure 6. c-Myc Inhibition Affects Transcription at the Pause-Release Step
(A) RNA was extracted frommES cells treated with 10058-F4 or vehicle alone (DMSO) for 6 hr and used to generate cDNA using reverse transcription. Expression
change was calculated for 10058-F4-treated cells compared to vehicle alone control for two non-c-Myc target genes (Brg1, Rnf2—green) and five c-Myc
target genes (Bax, Nol5, Zfp451, Brca2, and Atic—blue) from two independent experiments. Error bars represent standard deviation (SD) from triplicate
qPCR reactions.
(B) mES cells were treated with 10058-F4 for 1.5, 6, or 12 hr. Extracts were analyzed using western blot with antibodies against Pol II Ser2P CTD and Pol II Ser5P
CTD to determine the levels of the modified forms of Pol II. TBP was used as a loading control.
(C) Pol II ChIP-seq binding profiles in mES cells treated with 10058-F4 (c-Myc/Max inhibitor; blue), DMSO alone (black), or flavopiridol (P-TEFb inhibitor; red).
Pol II occupancy is shown for three c-Myc target genes (Ncl, Npm1, and Nol5) and two non-c-Myc target gene (Txnip and Chpf2). Cells were treated with 10058-
F4 or DMSO for 6 hr. See also Figure S6.
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Figure 7. Oct4 Shutdown Reduces Pol II
Initiation at Oct4-Dependent Genes
(A) Oct4 protein levels in doxycycline-inducible
Oct4 knockdown mES cells following 0, 12, or
24 hr of doxycycline treatment. Extracts were
probed with an antibody against Oct4. Brg1 was
used as a loading control.
(B) Pol II ChIP-seq binding profiles at Oct4 target
genes following the indicated time of doxycycline
treatment, inducing Oct4 knockdown. Of note,
the Oct4-bound genes change Pol II occupancy
in both the promoter-proximal region and the
transcribed region. The panel to the right shows
Pol II ChIP-seq binding profiles at non-Oct4 target
following the indicated time of doxycycline treat-
ment, inducing Oct4 knockdown.
(C) Pol II traveling ratio (TR) as described in
Figure 1C for the high-confidence Oct4-depen-
dent genes and Oct4 nontarget genes after either
0 or 12 hr of doxycycline treatment. The left panel
is the TR for the Oct4 targets and right panel is the
TR for non-Oct4 targets.amore general feature of transcription by Pol II in vertebrate cells
and identifies c-Myc as playing a key role in pause release at
a large population of actively transcribed genes in ES cells.
We describe several lines of evidence supporting the hypoth-
esis that promoter-proximal pausing is a general feature of
transcription by Pol II in ES cells. First, genome-wide analysis
shows that the bulk of Pol II occupies the promoter-proximal
region of genes, even when these genes are among the most
actively transcribed in the cell. Second, the pause factors DSIF
and NELF typically co-occupy these sites with Pol II, consistent
with the idea that they generally bind to the enzyme during early
steps of transcription elongation. Third, inhibition of the pause-
release factor P-TEFb prevents release of promoter-proximal
paused Pol II at essentially all genes.
A handful of genes have been identified that are regulated
by P-TEFb-dependent pause control, such as Hsp70 and cad
(Eberhardy and Farnham, 2002; Lis et al., 2000). However, in(D) Average Pol II binding plots for the high-confidence c-Myc targets and non-c-Myc target genes in no dr
panel shows the entire gene average. The right panel is a close-up of the transcribed region to show the diffe
the different conditions. Also included in the right panel for comparison is elongating Pol II density following
(E) Pol II traveling ratio (TR) for the high-confidence c-Myc target genes and non-c-Myc target genes follow
The left panel is the TR for the c-Myc targets and right panel is the TR for non-c-Myc targets. Higher TR va
Cell 141, 432–4retrospect, therewere a number of obser-
vations that indicated that this step in
transcription is more frequently regulated
and might be general. Germ cells repress
Pol II transcription globally by inhibiting
P-TEFb function. In C. elegans germline
blastomeres and in Drosophila primordial
germ cells, PIE-1 and Pgc, respectively,
repress global transcription by inhibiting
P-TEFb function (Hanyu-Nakamura
et al., 2008; Seydoux and Dunn, 1997;
Zhang et al., 2003). The transcription
factors of lentiviruses and retrovirusessuch as HIV and T-lymphotropic virus type I function by recruit-
ing P-TEFb to their promoter regions, attenuating Pol II transcrip-
tional pausing (Wei et al., 1998; Zhou et al., 2006). These viruses
have thus generated their own means to overcome pause
control.
The model that promoter-proximal pausing is general has
several implications for transcriptional control. A step subse-
quent to recruitment of the transcription initiation apparatus
can, in principle, be regulated at any gene. Promoter-proximal
pausing may facilitate assembly of RNA-processing factors
and has been proposed to couple transcription and mRNA-pro-
cessing events (Glover-Cutter et al., 2008;Moore and Proudfoot,
2009). DSIF and Ser5P Pol II can bind capping enzyme and stim-
ulate mRNA capping (Mandal et al., 2004; McCracken et al.,
1997a, 1997b; Wen and Shatkin, 1999). Ser2 phosphorylation
by P-TEFb leads to splicing factor and 30 end processing factor
recruitment and is required for proper processing (Ahn et al.,ug (black) and 10058-F4 treatment (blue). The left
rence in amounts of elongating Pol II density under
flavopiridol treatment (red).
ing 10058-F4 treatment (blue) or no drug (black).
lues indicate a higher degree of pausing.
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2004; Komarnitsky et al., 2000; McCracken et al., 1997b; Ni
et al., 2004). Promoter-proximal pausing also provides a mecha-
nism to control transcription from bidirectional promoters (Core
et al., 2008; Seila et al., 2008), perhaps facilitating the formation
of nucleosome-depleted regions and thus providing improved
access to regulators (Gilchrist et al., 2008).
Multiple lines of evidence support the contention that c-Myc/
Max generally plays a role in Pol II pause release at its target
genes in ES cells and does so through recruitment of P-TEFb.
Loss of c-Myc reduces the levels of elongating Pol II but does
not affect the levels of promoter-proximal Pol II. Inhibition of
c-Myc/Max function leads to a substantial reduction in the levels
of Ser2-phosphorylated Pol II in cells, which is the form associ-
ated with elongation, but does not affect the levels of Ser5-phos-
phorylated Pol II, which is the form associated with initiation.
c-Myc binds P-TEFb, which is responsible for Ser2-phosphory-
lated Pol II. Consistent with a role in pause release, c-Myc is
associated almost exclusively with genes that are actively tran-
scribed, unlike other key ES cell regulators like Oct4 and Nanog,
which occupy both active and repressed genes. Furthermore,
c-Myc occupies promoter-proximal sites (Figure S5A), which
are heavily enriched for the E-box core motif that it binds (Fig-
ure S5B), where c-Myc would be optimally positioned to recruit
P-TEFb.
In ES cells, c-Myc occupies genes involved in cellular prolifer-
ation, as it does in other cell types (Chen et al., 2008; Kidder
et al., 2008; Kim et al., 2008). Our results indicate that c-Myc
plays a key role in pause release in ES cells and does so at
perhaps 1/3 of all actively transcribed genes. These results
explain how ectopic expression of c-Myc can substantially
enhance the efficiency of reprogramming of fibroblasts to
induced pluripotent stem cells (Takahashi et al., 2007; Takahashi
and Yamanaka, 2006). Since c-Myc is expressed in a broad
spectrum of proliferating cell types (Eilers and Eisenman, 2008;
Meyer and Penn, 2008), and has been shown to bind P-TEFb
and stimulate elongation at a set of genes in tumor cells (Eber-
hardy and Farnham, 2001, 2002; Gargano et al., 2007; Kanazawa
et al., 2003), we expect that c-Myc functions to effect pause
release at this population of genes in most proliferating cells.
c-Myc amplification is the most frequent somatic copy-
number amplification in tumor cells (Beroukhim et al., 2010).
Our results suggest that tumor cells that overexpress c-Myc
have enhanced expression of proliferation genes due to the
role of c-Myc in recruiting P-TEFb to effect Pol II pause release
at these genes. It is therefore possible that combinations of
drugs that reduce the activity of both c-Myc and P-TEFb could
be especially effective therapeutic agents in tumor cells that
overexpress c-Myc.EXPERIMENTAL PROCEDURES
mES Cell Culture
V6.5 (C57BL/6-129) murine ES cells were grown under typical mES conditions
on irradiated mouse embryonic fibroblasts (MEFs). For location analysis, cells
were grown for two passages off of MEFs. For location analysis on mES cells
following treatment with small-molecule inhibitors, cells were grown two
passages off feeders, and prior to formaldehyde crosslinking, the cells were
treated with the indicated final concentration of flavopiridol (1 mM for 1 hr for
ChIP-chip and ChIP-seq experiments, or the indicated concentration and442 Cell 141, 432–445, April 30, 2010 ª2010 Elsevier Inc.time for western blot analysis) or c-Myc/Max inhibitor 10058-F4 (50 mM for
6 hr), both dissolved in DMSO, in the growth medium. As a control, DMSO
alone was added at the same final volume as with drug. Small-molecule
inhibitors used were as follows: flavopiridol (Sigma cat #F3055) and c-Myc
inhibitor 10058-F4 (Sigma cat #F3680). For location analysis following shRNA
knockdown (OpenBiosystems), viral media was collected 48 hr after cotrans-
fection in 293T cells and the mES cells were directly infected with the viral
media 24 hr after initial plating of mES cells. The infection media were 1:2 viral
media:mES media with 2 mM polybrene. The efficiently infected cells were
selected for 24 hr post-infection with mES media containing 2 mM puromycin.
Cells were crosslinked 72 hr post-selection. For location analysis following
Oct4 shutdown, ZHBTc4 mES cells (Niwa et al., 2000) were grown under
standard mES cell culture conditions and expanded for two passages off
MEF feeders. mES media with 2 mg/ml doxycycline were added to the cells
for 0 hr, 12 hr, and 24 hr prior to formaldehyde crosslinking.Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was done following the Agilent
Mammalian ChIP-on-chip protocol. The antibodies and ChIP conditions
used can be found in the Extended Experimental Procedures. For ChIP-chip
analysis, Cy3- and Cy5-labeled ligation-mediated PCR products were hybrid-
ized to a 44,000 feature Agilent mouse microarray. For ChIP-seq analysis,
Solexa/Illumina sequencing and analysis were done following the protocol
described in Marson et al. (2008). Refer to the Extended Experimental Proce-
dures for a detailed description of these methods.Active and Nonproductive Gene Classes
in mES Cells
The active and nonproductive genes were classified in mES cells using
H3K4me3 (initiation-associated chromatin modification) and H3K79me2
(elongation-associated chromatin modification), as determined by ChIP-seq
(Marson et al., 2008), as markers of transcriptional state. Active genes had
both H3K4me3 and H3K79me2 chromatin modifications, nonproductive
genes had only H3K4me3, and inactive genes did not have H3K4me3 or
H3K79me2 (Guenther et al., 2007; Marson et al., 2008; Pokholok et al., 2005).Traveling Ratio Calculation
Pol II levels peak in the 50 region ofmany genes. To quantify this effect, we have
developed a measure called traveling ratio (TR) that compares the ratio
between Pol II density in the promoter region and the gene region. We defined
the promoter region from30 to +300 relative to the TSS and the gene body as
the remaining length of the gene.Heatmap Analysis of ChIP-seq Data
ChIP-seq enrichment for the indicated factor or modification was determined
in 50 bp bins (enrichment in the bin as counts per million), centered on each
transcriptional start site. Generally, the gene list for each representation was
rank ordered based on the amount of Pol II (all) in mES cells, frommost to least
to correlate the enrichment of the given factor with the amount of Pol II at each
gene. Cluster 3.0 and Java Treeview were used to visualize the data and
generate figures shown in this manuscript.Previously Published ChIP-seq Datasets Used in This Study
Previously published datasets are as follows: H3K4me3, H3K79me2, and
Oct4 occupancy in mES cells (Marson et al., 2008); Nanog and c-Myc
occupancy in mES cells (Chen et al., 2008); and H3K27me3 occupancy in
mES cells (Mikkelsen et al., 2007).ACCESSION NUMBERS
The ChIP-seq and microarray data are deposited in GEO under accession
number GSE20485.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and three tables and can be found with this article online at
doi:10.1016/j.cell.2010.03.030.ACKNOWLEDGMENTS
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